IL4 and plexiform neurofibroma: In regard to NF1, we hypothesize that anti-IL-4 receptor monoclonal antibody dupilumab may inhibit the growth of neurofibromas, interfering with IL-4 and IL-13 binding to type I and type II receptors expressed on mast cells and fibroblasts.